StimCardio Medical Closes $30 Million Oversubscribed Series A To Advance Atrial Fibrillation Treatment

Los Angeles-based StimCardio Medical has closed an oversubscribed $30 million Series A round led by Metis MedTech, with participation from Catalyst Health Ventures, multiple corporate strategic investors, and other new and existing investors. The funding will support the clinical development of Rhyvive, an investigational wrist-worn device that uses non-invasive median nerve stimulation to treat atrial fibrillation, including the planned NeuroPulse 2 pivotal study.

Summary of transaction details:

• Deal Type: Series A
• Transaction Amount: $30,000,000
• Company: StimCardio Medical
• Founders: Amos Ziv & Tsahi Holand
• Headquarters: Los Angeles, California
• Notable Investors: Metis MedTech & Catalyst Health Ventures

StimCardio Medical is developing Rhyvive, a therapeutic device designed to deliver personalized, noninvasive median nerve stimulation targeting autonomic pathways involved in atrial fibrillation, a condition affecting approximately 59 million people worldwide. With a significant unmet clinical need, particularly given that 30% to 40% of patients experience recurrence following catheter ablation, this advancement may provide a novel treatment option. The company's founders, Amos Ziv and Tsahi Holand, are spearheading this innovative development in the medical technology sector.